AML GENE PANEL - BASIC (FLT3, NPM1, CEBPA)

An AML gene panel (basic) is advised by a hematologist at the time of AML diagnosis, ideally before starting treatment, especially when routine chromosome studies are normal. It helps assess risk and identify patients for FLT3-targeted therapy. It may also be repeated at relapse, and NPM1 is used to monitor residual disease.

No fasting is required for an AML gene panel (basic) done on a blood sample. If a bone marrow sample is needed, inform your doctor about blood thinners or bleeding disorders, and fast only if sedation is planned. Ideally, give the sample before starting chemotherapy. Samples must reach the lab promptly for accurate results.

No, fasting is not required for an AML gene panel (basic) when a blood sample is used. You can eat and drink normally. However, if the test is done on a bone marrow sample under sedation, you may need to fast for 4–6 hours. Follow your doctor’s specific instructions.